Alpine Immune Sciences is a clinical-stage immunotherapy company focusing on a new wave of immune therapeutics, creating potentially multifunctional immunotherapies to improve patients' lives via protein engineering technologies. The company has two keyprograms, ALPN-101 for autoimmune/inflammatory diseases, and ALPN-202 for the treatment of cancer. The company's proprietary scientific platform uses a process known as directed evolution to convert native immune system proteins from the Immunoglobulin Super Family, into multi-targeted therapeutics potentially capable of modulating the human immune system.

Altair Engineering is a technology company providing software and cloud solutions in the areas of product design and development, cloud computing, and data intelligence. The company's Software segment includes software and software related services. The software component of this segment includes its portfolio of software products including its solvers and optimization technology products. The company's client engineering services (CES), segment provides client engineering services to support its customers with long-term ongoing capability. The company operates its CES business by hiring engineers for placement at a customer site for specific customer-directed assignments.

Caledonia Mining Corporation is engaged in the acquisition, exploration and development of mineral properties for the exploitation of base and precious metals focused on Southern Africa. Co.'s primary asset is a 49% interest in the Blanket Mine in Zimbabwe which produced over 50,351 ounces of gold in 2016. Its segments include Corporate, Zimbabwe, and South Africa. The Corporate segment includes administrative functions within the group. The Zimbabwe segment comprise Caledonia Holdings Zimbabwe Ltd. and subsidiaries. The South Africa segment comprises a gold mine, that is on care and maintenance, as well as sales made by Caledonia Mining South Africa Proprietary Limited to the Blanket Mine.

CymaBay Therapeutics is a biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases with unmet medical need. The company's pipeline includes two clinical stage product candidates: seladelpar (MBX-8025), which is a potent and selective agonist of peroxisome proliferator activated receptor delta for the treatment of primary biliary cholangitis; and MBX-2982, which targets G protein-coupled receptor 119, a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. The company has one preclinical stage product candidate, CB-001, which targets G protein-coupled receptor 120.

Fiesta Restaurant Group is a holding company. Through its wholly-owned subsidiaries Pollo Operations, Inc. and its subsidiaries, and Pollo Franchise, Inc., (collectively Pollo Tropical) and Taco Cabana, Inc. and its subsidiaries (collectively Taco Cabana), the company owns, operates and franchises restaurant brands, Pollo Tropical? and Taco Cabana?. The company's Pollo Tropical restaurants provide fire-grilled chicken marinated in a proprietary blend of tropical fruit juices and spices. The company's Taco Cabana restaurants serve Mexican-inspired food, including tacos, flame-grilled USDA Choice steak and chicken fajitas, quesadillas, flautas, enchiladas, burritos, and salads served in its Cabana Bowl?.

Flexsteel Industries is a manufacturer, importer and marketer of residential and contract upholstered and wooden furniture products. With offerings for use in home, healthcare, and recreational seating, the company distributes its furniture throughout the United States and Canada through the company's sales force and various independent representatives. The company operates in one reportable segment, furniture products. The company's furniture products business involves the distribution of manufactured and imported products consisting of a line of upholstered and wooden furniture for residential and contract markets.

Gencor Industries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The company's products are: asphalt plants, which manufactures and produces hot-mix asphalt plants used in the production of asphalt paving materials; combustion systems and industrial incinerators, which manufactures combustion systems, soil remediation machinery, as well as combustion systems for rotary dryers, kilns, fume and liquid incinerators and fuel heaters; and fluid heat transfer systems, which manufactures the Hy-Way heat and Beverley lines of thermal fluid heat transfer systems and storage tanks for a range of industry uses.

Perma-Fix Environmental Services, through its subsidiaries, is an environmental and environmental technology company. The company has three segments: Treatment, which includes nuclear, low-level radioactive, mixed waste, hazardous and non-hazardous waste treatment, processing and disposal services, as well as research and development activities to identify, develop and implement waste processing techniques for problematic waste streams; Services, which includes on-site waste management services to commercial and governmental customers, and an equipment calibration and maintenance laboratory; and Medical, which includes research and development of the company's medical isotope production technology.

Royal Gold acquires and manages precious metal streams, royalties and similar interests. The company acquires existing stream and royalty interests or finances projects that are in production or in the development stage in exchange for stream or royalty interests. A metal stream is a purchase agreement that provides, in exchange for an upfront deposit payment, the right to purchase all or a portion of one or more metals produced from a mine, at a price determined for the life of the transaction by the purchase agreement. Royalties are non-operating interests in mining projects that provide the right to a portion of revenue or metals produced from the project after deducting specified costs, if any.

Plukka is engaged in the investment in securities listed on the Australian Stock Exchange and cash.

Viking Therapeutics is a biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. The company's main clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta in development for patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's second clinical program's primary drug candidate, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in development for patients recovering from non-elective hip fracture surgery. The company is also developing VK0214 for X-linked adrenoleukodystrophy.